Guangsheng Zhonglin

Guangsheng Zhonglin (Beijing) Pharmaceutical Technology is the dedicated innovative drug research and development subsidiary of Fujian Cosunter Pharmaceutical. Based in Beijing, the company focuses on the discovery and development of first-in-class and best-in-class small molecule therapeutics for liver diseases, oncology, and infectious diseases. Its primary strategic focus is achieving a functional cure for chronic Hepatitis B (HBV) through a multi-pronged approach targeting the viral core protein and surface antigens. The company also maintains a robust pipeline for Non-alcoholic steatohepatitis (NASH) and c-Met-driven cancers. Guangsheng Zhonglin serves as the core innovation engine for its parent company's transition from a generic manufacturer to an innovation-driven biopharmaceutical leader.